In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Patent infringement suit

This article was originally published in The Rose Sheet

Executive Summary

DermaQuest Skin Therapy has been dismissed from a patent infringement case by Allergan accusing eight companies of infringing a patent for the drug company's prostaglandin-based drug Lumigan, DermaQuest announces Jan. 11. The suit centers on the defendants' use of an ingredient used in Lumigan that reduces eye pressure in patients with glaucoma, but has the side effect of promoting eyelash growth. Allergan dismissed DermaQuest from the suit after the company proved its DermaLash lash-conditioning product did not contain the ingredient. However, Allergan is pressing on with its case against Jan Marini Skin Research regarding its Age Intervention eyelash products, although the beauty firm maintains it is not infringing any patents (1"The Rose Sheet" Jan. 14, 2008, p. 8)...

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts